-
31.发明公开公开(公告)号：US20230293536A1
公开(公告)日：2023-09-21
申请号：US18324511
申请日：2023-05-26
发明人： Tongtong XUE , Zhenwei MIAO , Jing WANG , Gang CHEN , Yan QING , Tong ZHU , Liang XIAO , Hong ZHANG , Qiuyan YANG , Dylan Dalun DENG , Liping LIU , Hong ZENG , Li YIN , Qifeng SHI , Hongmei SONG , Xi ZHAO , Lichun WANG , Jingyi WANG
CPC分类号： A61K31/536 , A61K47/6869 , A61K47/65 , A61K47/64 , A61K47/6803 , A61P35/00 , C07K16/32 , C07K2317/24
摘要： The present invention provides an anti-ErbB2 antibody-drug conjugate, a composition comprising the conjugate, a method for preparing the conjugate, and use of the conjugate.
-
公开(公告)号：US20230287122A1
公开(公告)日：2023-09-14
申请号：US17297719
申请日：2019-11-26
发明人： Liang XIAO , Liping DENG , Haiyu HUANG , Qigang LIU , Liping LIU , Dalton GUO , Tongtong XUE , Jingyi WANG
CPC分类号： C07K16/2827 , A61K47/02 , A61K47/26 , A61K47/22 , A61K9/08 , A61K39/39591 , C07K2317/565 , A61K2039/545
摘要： Provided is an anti-PD-L1 antibody preparation, including an anti-PD-L1 antibody, a buffer solution and sodium chloride, without added sugars and/or sugar alcohols. Also provided is the use of the anti-PD-L1 antibody preparation in the preparation of drugs for preventing and/or treating and/or adjuvant treating and/or diagnosing a tumor or anemia.
-
33.发明公开公开(公告)号：US20230203178A1
公开(公告)日：2023-06-29
申请号：US18008315
申请日：2021-06-25
发明人： Jianhui CHANG , Yanlin ZHU , Guangjun JING , Jingyi WANG , Jiangman WANG , Zhenzhen CAI , Panyan HOU , Liang XIAO , Tongtong XUE , Xiaodong WANG
IPC分类号： C07K16/28 , C07K14/705 , C07K14/725 , C12N5/0783 , A61K45/06 , A61K39/395 , A61K38/17 , A61K35/17 , A61P35/00
CPC分类号： C07K16/2878 , C07K16/2803 , C07K14/70517 , C07K14/70521 , C07K14/7051 , C07K14/70578 , C12N5/0636 , A61K45/06 , A61K39/3955 , A61K38/1774 , A61K38/177 , A61K35/17 , A61P35/00 , A61K2039/505
摘要： Provided are a chimeric antigen receptor (CAR) or CAR construct containing antibodies against BCMA and CD19, a nucleic acid molecule encoding the CAR or CAR construct, a modified immune cell, and a method for preparing the immune cell. The CAR or CAR construct and the modified immune cell are used for the prevention and/or treatment of B cell related conditions (e.g., B cell and plasma cell related malignant tumors or autoimmune diseases (such as systemic lupus erythematosus)), and can effectively avoid target escape and prevent the recurrence of multiple myeloma.
-
公开(公告)号：US20230192840A1
公开(公告)日：2023-06-22
申请号：US17295603
申请日：2019-12-19
发明人： Haijun TIAN , Sujun DENG , Chunxia ZHAO , Hong LI , Dengnian LIU , Hu LONG , Cheng WANG , Liang XIAO , Tongtong XUE , Jingyi WANG
IPC分类号： C07K16/28 , A61K47/68 , A61P35/00 , A61K31/337 , A61K39/395 , G01N33/574 , C07K16/46
CPC分类号： C07K16/28 , A61K47/6849 , A61P35/00 , A61K31/337 , A61K39/3955 , G01N33/57492 , C07K16/464 , A61K2039/505
摘要： The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.
-
公开(公告)号：US20220162199A1
公开(公告)日：2022-05-26
申请号：US17435031
申请日：2020-04-20
发明人： Jinming LIU , Yun REN , Qiang TIAN , Hongmei SONG , Tongtong XUE , Jingyi WANG
IPC分类号： C07D409/12 , C07D409/14
摘要： A compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug thereof, a pharmaceutical composition and a pill container comprising same, a preparation method therefor, and the use thereof in the preparation of drugs for preventing or treating STING-mediated related diseases.
-
公开(公告)号：US20210179647A1
公开(公告)日：2021-06-17
申请号：US17047000
申请日：2019-06-03
发明人： Qiang TIAN , Tianming WANG , Wei LIU , Baolei ZHANG , Mingliang ZHAO , Yufeng LIANG , Jiaqiang CAI , Lichun WANG , Jingyi WANG
IPC分类号： C07F9/6561 , C07F9/02
摘要： The present invention relates to compounds represented by formula (I) and formula (II) and a chiral synthesis and chiral isolation method therefor, further relating to a salt and crystal form of the compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the preparation of a medicament used for the treatment of a viral infectious disease such as hepatitis B.
-
公开(公告)号：US20210052576A1
公开(公告)日：2021-02-25
申请号：US16965450
申请日：2019-03-18
发明人： Yongyong WU , Jiaqiang CAI , Guangchao ZHANG , Shuangshuang DUAN , Chaolei WANG , Lichun WANG , Jingyi WANG
IPC分类号： A61K31/496 , A61P7/02 , C07D413/14 , C07D401/14 , A61K45/06 , A61K31/4725
摘要： Provided are tetrahydroisoquinoline derivatives, the preparation and use thereof. More specifically, provided are the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, isotopically labeled compound, metabolite or prodrug thereof. Further provided are a preparation process of the compound, the intermediates, a pharmaceutical composition comprising the compound and the use thereof in the treatment or prevention of a thromboembolic disorder.
-
公开(公告)号：US20200216538A1
公开(公告)日：2020-07-09
申请号：US16624408
申请日：2018-08-17
发明人： Tongtong XUE , Liang XIAO , Dengnian LIU , Hu LONG , Jiangjiang HU , Yamin CUI , Xiaoxi YUAN , Lichun WANG , Jingyi WANG
摘要： Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.
-
公开(公告)号：US20200179529A1
公开(公告)日：2020-06-11
申请号：US16497415
申请日：2018-04-12
发明人： Jiaqiang CAI , Tongtong XUE , Shuai SONG , Jing WANG , Qiang TIAN , Liang XIAO , Hanwen DENG , Liping LIU , Zujian TANG , Hong ZENG , Rongrong LONG , Hongmei SONG , Qiang ZHANG , Guoqing ZHONG , Dengnian LIU , Haitao HUANG , Ruibin HU , Lichun WANG , Jingyi WANG
IPC分类号： A61K47/68 , A61K47/62 , A61P35/00 , A61K31/5386 , A61K38/07
摘要： Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3ζ molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.
-
公开(公告)号：US20200039978A1
公开(公告)日：2020-02-06
申请号：US16499610
申请日：2018-05-28
发明人： JIANHUA GE , Zengying HAN , Fengchun CHEN , Shihu JIAO , Hong ZHANG , Ping ZHANG , Lichun WANG , Jingyi WANG
IPC分类号： C07D471/04 , A61P19/02
摘要： The present invention relates to a solid form of a compound of Formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and use of the solid form in the treatment of Janus kinase (JAK) related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.025 秒)
